Patten & Patten Inc. TN lifted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 176,814 shares of the biopharmaceutical company’s stock after purchasing an additional 9,251 shares during the period. Bristol-Myers Squibb accounts for 1.1% of Patten & Patten Inc. TN’s portfolio, making the stock its 28th largest holding. Patten & Patten Inc. TN’s holdings in Bristol-Myers Squibb were worth $10,835,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in BMY. Steward Partners Investment Advisory LLC boosted its holdings in Bristol-Myers Squibb by 11.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 44,579 shares of the biopharmaceutical company’s stock valued at $2,731,000 after purchasing an additional 4,569 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $458,000. Naples Global Advisors LLC boosted its holdings in Bristol-Myers Squibb by 6.3% in the 4th quarter. Naples Global Advisors LLC now owns 17,668 shares of the biopharmaceutical company’s stock valued at $1,083,000 after purchasing an additional 1,049 shares during the period. Hollencrest Capital Management boosted its holdings in Bristol-Myers Squibb by 19.9% in the 4th quarter. Hollencrest Capital Management now owns 9,053 shares of the biopharmaceutical company’s stock valued at $555,000 after purchasing an additional 1,500 shares during the period. Finally, State of Alaska Department of Revenue boosted its holdings in Bristol-Myers Squibb by 1,205.4% in the 4th quarter. State of Alaska Department of Revenue now owns 159,645 shares of the biopharmaceutical company’s stock valued at $9,780,000 after purchasing an additional 147,415 shares during the period. Institutional investors own 70.57% of the company’s stock.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by corporate insiders.
A number of research firms have issued reports on BMY. ValuEngine downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday. Bank of America upped their price target on shares of Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a report on Monday. DZ Bank downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Jefferies Group set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 26th. Finally, Citigroup set a $78.00 price target on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, February 16th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $66.30.
Bristol-Myers Squibb Co (BMY) opened at $65.47 on Wednesday. The stock has a market cap of $109,089.20, a price-to-earnings ratio of 22.20, a P/E/G ratio of 2.08 and a beta of 0.98. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. Bristol-Myers Squibb’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 earnings per share. analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.44%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.